Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.58 |
| ▸ | TGM2 | P21980 | 10/20 | 0.50 |
| ▸ | F13A1 | P00488 | 7/20 | 0.50 |
| ▸ | TGM1 | P22735 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19127388 | 0.86 | GPR119 (0.54) | GPR119GRM5GRM1 | |
| SCHEMBL19126721 | 0.84 | GPR119 (0.58) | GPR119CA12CA1CA2CA9 | |
| SCHEMBL19126753 | 0.83 | GPR119 (0.52) | GPR119CA12CA1CA2CA9 | |
| SCHEMBL19126554 | 0.82 | GPR119 (0.51) | GPR119GRM5GRM1 | |
| SCHEMBL19146302 | 0.81 | GPR119 (0.50) | GPR119CA12CA1CA2CA9 | |
| SCHEMBL19126500 | 0.80 | GPR119 (0.49) | GPR119GRM5GRM1 | |
| SCHEMBL19126818 | 0.79 | GPR119 (0.48) | GPR119CA12CA1CA2CA9 | |
| SCHEMBL19126575 | 0.79 | GPR119 (0.48) | GPR119GRM5GRM1 | |
| SCHEMBL19145401 | 0.78 | GPR119 (0.49) | GPR119GRM5GRM1P2RY14 | |
| SCHEMBL19126542 | 0.78 | GPR119 (0.52) | GPR119GRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028687-A1 | QUINOLIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-11186562-B2 | Quinolin-2-one derivatives | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | disclosed |
| US-11174241-B2 | Quinolin-2-one derivatives | MERCK PATENT GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-20200190054-A1 | QUINOLIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20200190055-A1 | QUINOLIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-10669251-B2 | Quinolin-2-one derivatives | MERCK PATENT GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| US-20190023685-A1 | QUINOLIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174241-B2 | Quinolin-2-one derivatives | KIT, CDK2, CDK1 | GPR119 1948/4885TGM2 2109/4885F13A1 393/4885 |
| US-20190023685-A1 | QUINOLIN-2-ONE DERIVATIVES | KIT, CDK2, CDK1 | GPR119 1948/4885TGM2 2109/4885F13A1 393/4885 |
| US-20200190054-A1 | QUINOLIN-2-ONE DERIVATIVES | KIT, CDK2, CDK1 | GPR119 1948/4885TGM2 2109/4885F13A1 393/4885 |
| US-20230028687-A1 | QUINOLIN-2-ONE DERIVATIVES | KIT, CDK2, CDK1 | GPR119 1948/4885TGM2 2109/4885F13A1 393/4885 |
| US-20200190055-A1 | QUINOLIN-2-ONE DERIVATIVES | KIT, CDK2, CDK1 | GPR119 1948/4885TGM2 2109/4885F13A1 393/4885 |
| US-10669251-B2 | Quinolin-2-one derivatives | KIT, CDK2, CDK1 | GPR119 1948/4885TGM2 2109/4885F13A1 393/4885 |
| US-11186562-B2 | Quinolin-2-one derivatives | KIT, CDK2, CDK1 | GPR119 1948/4885TGM2 2109/4885F13A1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.